Early Melanoma Nodal Positivity and Biopsy Rates Before and After Implementation of the 7th Edition of the AJCC Cancer Staging Manual.

Early Melanoma Nodal Positivity and Biopsy Rates Before and After Implementation of the 7th Edition of the AJCC Cancer Staging Manual.

Publication date: Mar 06, 2019

There has been a continued increase in the incidence of newly diagnosed melanomas, most of which are T1 melanomas. The associations between changes in tumor staging, implemented with the 7th edition of the AJCC Cancer Staging Manual (AJCC 7), and sentinel lymph node biopsy rates and nodal positivity rates remain to be seen.

To evaluate the change that the implementation of the AJCC 7 had on staging criteria and the distribution of thin melanomas requiring nodal surgery and nodal positivity rates.

Retrospective cross-sectional study from 2004 through 2013 of all adults (≥18 years) diagnosed with a T1 (Breslow depth ≤1.0 mm) melanoma using The National Cancer Database that captures 70% of all newly diagnosed cancers from accredited Commission on Cancer organizations, including both academic and community settings. Data were analyzed in May 2017.

Patients were grouped together based on year of diagnosis, before and after 2009.

To determine the sentinel lymph node biopsy rate before and after the implementation of the AJCC 7.

A total of 141 280 patients met inclusion criteria. Of 86 846 patients diagnosed from 2004 through 2009, 53.7% (49 644) were male and had a mean (SD) age of 57.7 (16.4) years. Of 54 434 patients diagnosed from 2010 through 2013, 54.3% (31 086) were male and had a mean (SD) age of 59.5 (15.9) years. After 2010, there was a 3.8% decrease in the number of nodal surgeries performed (32 485 of 86 846 patients [37.6%] vs 18 379 of 54 434 patients [33.8%]; P 

Isom, C., Wheless, L., Hooks, M.A., and Kauffmann, R.M. Early Melanoma Nodal Positivity and Biopsy Rates Before and After Implementation of the 7th Edition of the AJCC Cancer Staging Manual. 21880. 2019 JAMA Dermatol.

Concepts Keywords
AJCC Breslow’s depth
Biopsy Lymph node biopsy
Cross Sentinel lymph node
Incidence Melanoma
JAMA RTT
Melanoma Cancer staging
Melanomas Clinical medicine
Nodal Medical specialties
Tumor Medicine
Surgeries
Surgery
Melanomas melanomas tumor
Cancers

Semantics

Type Source Name
gene UNIPROT RNMT
gene UNIPROT MET
gene UNIPROT SLTM
drug DRUGBANK Methionine
disease MESH diagnosis
disease MESH community
disease DOID Cancer
disease MESH Cancer
gene UNIPROT NODAL
pathway BSID Melanoma
disease DOID Melanoma
disease MESH Melanoma

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *